Endpoints News | Nachrichten

Zeit	Aktuelle Nachrichten
Fr	Tropical disease PRV fix didn't stop Novartis from winning another
Fr	FDA doc reveals agency charged Immunomedics with data integrity breach after August plant inspection
Fr	J&J R&D vet Peter Tummino joins the Big Pharma exodus, leaping to Nimbus as CSO; Cadent taps Jodie Morrison for CEO
Fr	GW Pharma cannabinoid to be tested for Alzheimer's agitation; Acorda revenue plummets as generics eviscerate its franchise
Fr	Morningside spawned Stealth Bio's IPO stumbles out of the gate, raising $78M
Fr	Bayer, Orion prostate cancer drug cuts risk of metastasis or death by more than 50% in key study
Fr	James Wilson turns to old mentor for gene therapy startup's star-studded $115M launch round
Fr	The top 10 pipeline blowups, setbacks and snafus for H2 2018
Fr	India's generic drug maker Glenmark draws up a US-based branded drugs unit
Fr	Appropriations bill would give FDA $269M boost over FY2018 budget
Do	Merck goes in deeper with Keytruda/Lynparza combo; PureTech unveils stem cell therapy startup
Do	Antipsychotic from Lundbeck, Otsuka flops again in PhIII trials - this time in bipolar patients
Do	Motif Bio's turnaround quest for once-rejected antibiotic hits the CRL wall
Do	Vivek Ramaswamy whips up a CNS spinoff with a $530M deal and a syndicate of supporters
Do	David de Graaf has a new gig, a new idea and a new startup - hunting some new money
Do	AstraZeneca drops an OX40 cancer drug candidate in Q4 pipeline cleanup
Do	DBV estimates peanut allergy drug submission in Q3, but it may be too little too late in race with Aimmune
Do	In HKEX's first test in 2019, CStone seeks up to $304M in IPO fortune
Do	AstraZeneca sweeps away the MedImmune name as CEO Soriot restructures R&D
Do	Donated globally since 2005, Novartis' flatworm treatment Egaten wins FDA nod - and a PRV
Mi	Charles River drops $510M to bag non-clinical CRO; Magpie raises $14.8M Series B to modernize traditional Chinese meds
Mi	Vas Narasimhan earned a big pay hike when he moved to the CEO's suite at Novartis
Mi	J&J to augment surgical offerings with $3.4B acquisition of robotics firm Auris Health
Mi	Busy VC 5AM eclipses $125M target for fund to inject capital into existing portfolio, meets goal for sixth biotech fund - report
Mi	The $100M biotech club: Who's in, and what's it take to join the top-performing group of biopharmas?

Zeit

Aktuelle Nachrichten

Tropical disease PRV fix didn't stop Novartis from winning another

FDA doc reveals agency charged Immunomedics with data integrity breach after August plant inspection

J&J R&D vet Peter Tummino joins the Big Pharma exodus, leaping to Nimbus as CSO; Cadent taps Jodie Morrison for CEO

GW Pharma cannabinoid to be tested for Alzheimer's agitation; Acorda revenue plummets as generics eviscerate its franchise

Morningside spawned Stealth Bio's IPO stumbles out of the gate, raising $78M

Bayer, Orion prostate cancer drug cuts risk of metastasis or death by more than 50% in key study

James Wilson turns to old mentor for gene therapy startup's star-studded $115M launch round

The top 10 pipeline blowups, setbacks and snafus for H2 2018

India's generic drug maker Glenmark draws up a US-based branded drugs unit

Appropriations bill would give FDA $269M boost over FY2018 budget

Merck goes in deeper with Keytruda/Lynparza combo; PureTech unveils stem cell therapy startup

Antipsychotic from Lundbeck, Otsuka flops again in PhIII trials - this time in bipolar patients

Motif Bio's turnaround quest for once-rejected antibiotic hits the CRL wall

Vivek Ramaswamy whips up a CNS spinoff with a $530M deal and a syndicate of supporters

David de Graaf has a new gig, a new idea and a new startup - hunting some new money

AstraZeneca drops an OX40 cancer drug candidate in Q4 pipeline cleanup

DBV estimates peanut allergy drug submission in Q3, but it may be too little too late in race with Aimmune

In HKEX's first test in 2019, CStone seeks up to $304M in IPO fortune

AstraZeneca sweeps away the MedImmune name as CEO Soriot restructures R&D

Donated globally since 2005, Novartis' flatworm treatment Egaten wins FDA nod - and a PRV

Charles River drops $510M to bag non-clinical CRO; Magpie raises $14.8M Series B to modernize traditional Chinese meds

Vas Narasimhan earned a big pay hike when he moved to the CEO's suite at Novartis

J&J to augment surgical offerings with $3.4B acquisition of robotics firm Auris Health

Busy VC 5AM eclipses $125M target for fund to inject capital into existing portfolio, meets goal for sixth biotech fund - report

The $100M biotech club: Who's in, and what's it take to join the top-performing group of biopharmas?

Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von

Indizes	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage

Aktien	Kurs	%	News 24 h / 7 T	Aufrufe 7 Tage

Xetra-Orderbuch

Devisen	Kurs	%

Rohstoffe	Kurs	%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)

Aktuelle News von Endpoints News